Skip to content
Screener

EyePoint, Inc. EYPT Shares (Diluted)

Shares (Diluted) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
106M-2.4%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
224.1M+32.3%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
61.9M+17.3%
Regenxbio logo
RegenxbioRGNX
53M+3.0%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
68.1M+22.1%
KLR
Kalaris TherapeuticsKLRS
23.7M+485%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Net loss per share:
Basic and diluted$(1.09)$(0.85)$(2.08)$(1.50)
Weighted average common shares outstanding:
Basic and diluted86,54369,92686,27269,847
Net loss$(94,470)$(59,426)$(179,302)$(104,621)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities(9)(91)(168)(196)
Comprehensive income (loss)$(94,479)$(59,517)$(179,470)$(104,817)

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s shares (diluted)?
EyePoint, Inc. (EYPT) reported shares (diluted) of 86.5M in Q2 2026.
How has EyePoint, Inc.'s shares (diluted) changed year-over-year?
EyePoint, Inc.'s shares (diluted) increased by 23.8% year-over-year, from 69.9M to 86.5M.
What is the long-term trend for EyePoint, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), EyePoint, Inc.'s shares (diluted) has grown at a 26.4% compound annual growth rate (CAGR), from 111M to 283.1M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about EyePoint, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude